Maltose Falsely Elevated Diabetics' Readings: FDA

Law360, New York (April 23, 2008, 12:00 AM EDT) -- The U.S. Food and Drug Administration said in a final report issued last week it had identified seven adverse events, including two deaths, in diabetic patients who received immune globulin products containing sugar maltose.

The agency released its report concerning maltose, which functions as a protein stabilizer and an osmotic agent, on April 17.

The agency's three-year investigation was launched in July 2005, when the FDA received a case report of an elderly male diabetic patient who received a 10% maltose-containing intravenous immune globulin product after...
To view the full article, register now.